Clinical Study

Prevalence and Clinical and Immunoviralogical Profile of Human Immunodeficiency Virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, Nigeria

Emmanuel Ademola Anigilaje¹ and Ayodotun Olutola²

¹ Department of Paediatrics, Federal Medical Centre, PMB 12245, Makurdi, Benue State, Nigeria
² Center for Clinical Care and Clinical Research, 29 Mambilla Street, Off Aso Drive, Maitama, Abuja, Nigeria

Correspondence should be addressed to Emmanuel Ademola Anigilaje; demolaanigilaje@yahoo.co.uk

Received 25 February 2013; Accepted 17 March 2013

Academic Editors: M. Adhikari, G. J. Casimir, J. A. O’Neill, and G. K. Siberry

Copyright © 2013 E. A. Anigilaje and A. Olutola. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Nigeria has the world largest burden of paediatric HIV and is also highly endemic for Hepatitis B virus (HBV). However, relatively little is known regarding the prevalence of HBV-HIV coinfections among Nigerian children. Methods. A retrospective study among treatment naive HIV-infected children attending the pediatric clinic of the APIN Plus/Harvard PEPFAR program of the Federal Medical Centre, Makurdi, between June 2008 and June 2012. Results. The mean age of the 395 subjects studied was 7.53 ± 4.23 years. Thirty-one subjects (7.8%) were positive for HBV. No subject was HIV-HBV-HCV triply infected. Significantly higher HIV-HBC coinfections were found, in older subjects (11–15 years), subjects that did not receive nor complete Hepatitis B vaccinations, and subjects that had a severe immunosuppression of <15% with respective P values of 0.00, 0.01, and 0.00. HIV-HBV co-infection did not significantly impact on other baseline characteristics including, gender, WHO clinical stage, median absolute CD4 count, mean viral load, median ALT, and hepatotoxicity. Conclusion. A high seroprevalence of HBV among this cohort of HIV-infected children contributes to the calls for pre-ART screening for HBV and the necessary paradigm shift in the ART nucleoside backbone to include agent(s) more dually effective against HIV and HBV.

1. Introduction

With an estimation of 250,000 children infected with HIV, Nigeria accounts for more than 10% of the global paediatric HIV burden [1]. More than 90% of these infections were vertically acquired from mother to child. Nigerian coverage of Prevention of Mother to Child Transmission (PMTCT) strategies has meagerly increased from 5.3% in 2007 to 11% in 2010 [2]. This implies that many new paediatric infections continue to occur, with Nigeria accounting for 30% of the global PMTCT gaps [1]. Regional differences in the HIV burden exist in Nigeria. Benue State, located in the North Central region, had the highest estimated HIV prevalence of 12.7% in 2010 [2–4]. Several other pathogens including Hepatitis B virus are acquired vertically with the attendant risks of coinfections and the complex interactions. Nigeria is also known to be highly endemic for Hepatitis B viral (HBV) infection [5]. There is a relative paucity of data on HIV/HBV coinfection. A few studies have reported rates ranging from prevalence of 7.7%, to 19% of HIV-HBV coinfections in Nigerian children [6–8]. Precariously, the prevalence of pediatric HBV-HIV coinfections may be higher as most HBV infections occur within the first 5 years of life in children in Africa [9]. In addition, Mbaawuaga et al. [10] had earlier demonstrated a high sero-prevalence of 11% of HBV infection with infectivity rates of 3.3% among pregnant women in Makurdi, Benue State. Complex interactions between HIV and HBV have been well documented in adult population [11–18]. Higher HBV DNA levels have been found in those coinfected with HIV and HBe antibody seroconversion occurring less frequently in HIV-coinfected individuals, thereby delaying transition to
the inactive carrier state with its attendant higher risk of advanced liver disease [11–14]. The impact of HBV on HIV disease is less clear. Whilst one study showed an increased rate of HIV progression to AIDS [15], others investigators did not show any change in the progression of HIV disease or survival [16]. However, coinfection with HBV has been associated with increased hepatotoxicity to highly active antiretroviral therapy (HAART) [17, 18]. With easy access to and success of HAART in reducing mortality from AIDS, longevity means that coinfected children are more exposed to the aforementioned complex interactions. The need to document the burden of HIV-HBV coinfections in Nigerian children like any others can no longer be overemphasized. This study therefore determined the prevalence proportion, clinical, demographic, and immunovirological characteristics of HIV-HBV coinfections among children receiving care and treatment for HIV/AIDS in a tertiary health centre in Makurdi, Benue State, Nigeria.

2. Methods

The study was carried out among HIV-infected children receiving care and treatment at the Paediatric ART (Antiretroviral therapy) Clinic of the Riverside Specialist Clinics of the Federal Medical Centre (FMC), Makurdi. FMC, Makurdi, is the only tertiary health hospital providing care and treatment for paediatric HIV in Benue State and, therefore, is a referral centre for primary and secondary health facilities in Benue State and the surrounding states of Taraba, Nasara, and Kogi. The facility is supported by the AIDS Prevention Initiative in Nigeria (APIN)/Harvard PEPFAR (The USA President's Emergency Plan for AIDS Relief) program providing ART to HIV-infected children according to the Nigerian Guidelines on Paediatric HIV/AIDS Treatment and Care. Ethical approval for the study was obtained from the Hospital Research and Ethics Committee. HIV-infected children are recruited into care and treatment upon consent of parents/caregivers and assent of the child if older than age of 7 years. Inclusion criteria included subjects who were screened and got results for Hepatitis B surface antigen and HCV antibody at the time of the HIV diagnosis and before the commencement of ART over the study period, between June 2008 and June 2012. A study proforma was designed to extract the following information from the subjects' data bank at recruitment: age, sex, immunization history, mode of transmission of HIV, WHO clinical staging, CD4+ counts, CD4%, HIV viral load, and alanine transaminase (ALT) level. All subjects ≥18 months had an initial double rapid HIV antibody tests using Determine HIV 1/2 (by Abbott Japan Co., Ltd. Minato-Ku, Tokyo, Japan) first and then HIV 1/2STAT-PAK (by Chembio Diagnostics Systems, Inc., Medford, NY 11763, USA) in serial algorithm. HIV infection was confirmed in subjects who had reactive rapid test by using a Western Blot test. Two HIV DNA PCR positivity tests for those <18 months confirmed HIV infection in this age group. Detection of HBsAg and HCV was done using the third generation ELISA technique for both HBsAg (ELAgen HBsAg Kit) and HCV antibody (ELAgen HCV Ab Kit). The tests were done according to the instructions of the manufacturer (Diaspot, USA). Catalytic activity of ALT was determined in serum using a Cobas Mira chemistry analyzer (GMI, MI, USA) after it was calibrated. All tests were done in the APIN/PEPFAR laboratory of the hospital.

2.1. Definitions. HBsAg status is defined as either HBsAg positive/HIV-HBV co-infected or HBsAg negative. Hepatotoxicity was defined as ALT 1.25-fold over the upper limit of normal (ULN is 37 iu/l) [19]. Levels of immunological suppression were defined as severe when the CD4% <15, moderate when the CD4% is between 15 and 25, and mild when CD4% >25. Only one or two doses of Hepatitis B vaccine were considered to be incomplete, and three doses were considered to be complete.

2.2. Data Analysis. Data were analyzed using SPSS version 19. The overall seroprevalence of HBsAg was expressed in percentages and by age and gender. Chi-Square ($\chi^2$) was used to determine the association between HBsAg status and age groups, gender, HBV immunization status, WHO clinical stages, and hepatotoxicity. Fisher’s exact test was employed to test the association between HBsAg status and routes of HIV acquisitions and ranges of CD4% immunosuppression. Plotted histogram and normal probability curves were used to test for normality of CD4 counts, viral load, and ALT, and only viral load was found to be normally distributed. Medians of CD4 counts and ALT levels of recruitment between HIV-monoinfected and HIV-HBV-coinfected groups were compared using the Mann-Whitney u test. Also, the means of age and the means of Log10 viral load were compared using unpaired t-test between HIV-monoinfected and HIV-HBV-coinfected groups. $P < 0.05$ was taken as significant.

3. Results

3.1. Clinical and Demographic Characteristics of Subjects (Table 1). A total of 936 children were seen within the study period (from June 2008 to June 2012), but only 395 subjects were screened and received results for viral Hepatitis B and C. The remaining 541 were not screened for reasons bordering on failure to request for screening for the viral hepatitis and occasional instances when the testing kits went out of stock. Among the 395 subjects screened, 31 subjects (7.8%) were positive for HBV. Nine subjects (2.3%) were positive for Hepatitis C. No subject was positive for both HBV and HCV. The mean age for the 395 subjects was 7.53 ± 4.23 years. The age range was from 8 months to 15 years. There were 205 males and 190 females with an M : F ratio of 1 : 0.9. The majority, 159, was less than 5 years, while others were fairly distributed within the age group of 6–10 years (122) and 11–15 years (114).

3.2. Clinical, Demographic, and Laboratory Characteristics of HIV-HBV Coinfection Status Groups (Table 2). In order to remove the possible confounding effect of HCV infection, only 386 subjects (excluding 9 who tested positive for HCV) were tested for the effect of HIV-HBV co-infection on WHO
clinical stage, CD4 counts and CD4%, viral load, and ALT. Out of these 386 subjects, 108 (27.9%) data were missing for CD4 count/CD4%, 118 (30.6%) data were missing for viral load, and only 8 data (2.1%) were missing for ALT. Again, reasons for missing data included occasional instances when testing kits went out of stock, insufficient and spilled blood samples, and equipment breakdown especially during the early period of the program.

3.3. HIV-HBV Coinfections by Age and Gender. The mean ages of 9.74 ± 4.08 and 7.34 ± 4.19 years were compared between dually infected and HIV-monoinfected subjects, respectively, and were significant, (P value 0.00). The majority, (17, 14.9%) of HIV-HBV viral co-infections were in the 11–15 year group and were significant (P value 0.00). Although more female subjects (19, 10%) were dually infected with HIV and HBV than male subjects (12, 5.9%), this was not statistically significant (P value 0.18).

3.4. HIV-HBV Coinfections and HBV Immunizations. Hepatitis B viral co-infection was found among subjects that did not receive or complete Hepatitis B vaccinations (20, 6.1%) compared to subjects that had (11, 16.7%) the three doses of Hepatitis B vaccinations, and this was found to be significant (P value 0.01).

3.5. HIV-HBV Coinfections and Route of HIV Acquisitions. The majority of the subjects (27, 7.9%) that were co-infected with Hepatitis B viral infection also acquired the HIV infection via Mother to Child Transmission; this was not statistically significant. Only one subject (14.3%) who acquired HIV infection via blood transfusion was also coinfected with HBV. The route of acquisition of HIV for three subjects with HIV-HBV viral coinfection could not be ascertained: P value of 0.55.

3.6. HIV-HBV Coinfections and WHO Clinical Staging. Although the majority of HIV-HBV-co-infected subjects (21, 7.7%) were recruited in WHO clinical stages 1 and 2, the finding was not statistically significant (P value 0.91).

3.7. HIV-HBV Coinfections and Baseline Laboratory Findings. A lower median absolute CD4 count of 334 cells/mL (IQR from 182.50 to 830.50) was found among HIV-HBV co-infected subjects compared to a median of 560 cells/mL (IQR from 275.00 to 916.80) among HIV-monoinfected subjects (P value 0.11). Furthermore, 15.8% (12) of HIV-HBV-coinfected subjects had a severe immunosuppression of <15% and was significant (P value 0.00).

Table 1: Clinical and demographic characteristics of subjects.

| Characteristics               | Number | Percentage |
|-------------------------------|--------|------------|
| Mean age ± standard deviation | 7.53 ± 4.23 |
| Gender                        |        |            |
| Male                          | 205    | 51.9       |
| Female                        | 190    | 48.1       |
| Total                         | 395    | 100.0      |
| Age groups in years           |        |            |
| < 5                           | 159    | 40.3       |
| 6–10                          | 122    | 30.8       |
| 11–15                         | 114    | 28.9       |
| Total                         | 395    | 100.0      |
| Hepatitis BsAg status groups  |        |            |
| Positive (HIV-HBV dually infected) | 31  | 7.8        |
| Negative                      | 364    | 92.2       |
| Total                         | 395    | 100.0      |
| Hepatitis C antibody status groups |   |            |
| Positive (HIV-HCV dually infected) | 9  | 2.3        |
| Negative                      | 386    | 97.7       |
| Total                         | 395    | 100.0      |

The mean viral load was comparable among both groups with 4.26 ± 1.29 among the HIV-HBV co-infected subjects and 4.51 ± 1.17 among the HIV-monoinfected subjects but was not significant (P value 0.33).

4. Discussion

The prevalence of 7.8% for Hepatitis B surface antigen in this study is similar to 7.7% described by Sadoh et al. [6] in Benin, Nigeria, but higher than the respective sero-prevalence of 1.2%, 2.6%, 4%, and 4.9% reported by Telatela et al. [20] in Nigeria, but higher than the respective sero-prevalence of 7.7% described by Sadoh et al. [6] in Benin, Nigeria. Above all, Bukbuk et al. [28] reported a prevalence...
Table 2: Clinical, demographic, and laboratory characteristics of HIV-HBV coinfection status groups.

| Characteristics                                      | Hepatitis BsAg positive (HIV-HBV dually infected) | Hepatitis BsAg negative | Missing data | P value |
|------------------------------------------------------|--------------------------------------------------|-------------------------|--------------|---------|
| Mean age in years ± SD                                | 9.74 ± 4.08                                      | 7.34 ± 4.19             |              | 0.00    |
| Age group in years                                   |                                                 |                         |              |         |
| ≤5                                                   | 6                                                | 153                     |              | 0.00    |
| 6–10                                                 | 8                                                | 114                     |              |         |
| 11–15                                                | 17                                               | 97                      |              |         |
| Total                                                | 31                                               | 364                     |              |         |
| Gender                                               |                                                 |                         |              |         |
| Male                                                 | 12                                               | 193                     |              | 0.18    |
| Female                                               | 19                                               | 171                     |              |         |
| Total                                                | 31                                               | 364                     |              |         |
| HBV immunization                                     |                                                 |                         |              |         |
| None/incomplete                                      | 20                                               | 309                     |              | 0.01    |
| Complete                                             | 11                                               | 55                      |              |         |
| Total                                                | 31                                               | 364                     |              |         |
| Route of HIV acquisitions                            |                                                 |                         |              |         |
| MTCT                                                 | 27                                               | 339                     |              | 0.55    |
| Blood transfusion                                    | 1                                                | 6                       |              |         |
| Others (sexual)                                      | 0                                                | 2                       |              |         |
| Unknown                                              | 3                                                | 17                      |              |         |
| Total                                                | 31                                               | 364                     |              |         |
| WHO staging*                                         |                                                 |                         |              |         |
| 1 and 2                                              | 21                                               | 250                     |              | 0.91    |
| 3 and 4                                              | 10                                               | 105                     |              |         |
| Total                                                | 31                                               | 355                     |              |         |
| Absolute CD4 count in cells/mm, median (IQR)*        | 334.00 (182.50–830.50)                            | 560.00 (275.00–916.80) | 108          | 0.11    |
| CD4%*                                                |                                                 |                         |              |         |
| <15                                                  | 12                                               | 64                      |              | 0.00    |
| 15–25                                                | 2                                                | 50                      |              |         |
| >25                                                  | 6                                                | 144                     |              |         |
| Total                                                | 20                                               | 258                     |              |         |
| Log_{10} viral load, Mean ± SD*                      | 4.26 ± 1.29                                      | 4.51 ± 1.17             | 118          | 0.33    |
| ALT, Median (IQR)*                                   | 30.20 (18.50–50.70)                              | 24.70 (16.65–35.32)     | 8            | 0.08    |
| Hepatotoxicity*                                      |                                                 |                         |              |         |
| Normal                                               | 20                                               | 270                     |              | 0.43    |
| Elevated                                             | 11                                               | 77                      |              |         |
| Total                                                | 31                                               | 347                     |              |         |

SD: standard deviation.
IQR: interquartile range.
* Data of 9 subjects (HIV-HCV coinfected) were excluded.

of 44.7% among pupils in primary school in rural Borno, Nigeria. Where as the shared modes of transmission of HBV and HIV would explain the high prevalence of HBsAg among HIV-infected children in our study and those of others [6–9, 20–23], the differences in subjects’ selection as well as diverse socioeconomic and demographic risk factors that favored horizontal transmissions of HBV in the different settings of the non-HIV-infected children may explain the different seroprevalence of HBV in other studies [24–28]. For example, unsafe injection from unqualified medical personnel using HBV contaminated needle and syringe, transfusion of blood and blood products, and sociocultural practices such as tribal marks, circumcision, and scarification were important routes
of HBV transmission in the study by Ugwuja and Ugwu [25]. Jafri et al. [24] in Pakistan also identified inappropriate injections using new or reused needles and syringes and the use of multiple-dose vials as horizontal risk factors for HBV contraction. However, Angyo and Yakubu [27] did not find a significant association between HBV surface antigenemia and the potential risk factors including blood transfusion, parenteral injections, hospitalization, traditional ukulectomy, circumcision, ear piercing, traditional scarifications, and contacts with case of known Hepatitis in cohorts of children with sickle cell anaemia and those with haemoglobin AA.

A significant number of our subjects (17, 14.9%) that were seropositive for HBV were found to be adolescents between the ages of 11–15 years. A similar trend was noticed by Zhou et al. [23] in China whereby children older than 11 years were significantly more infected with HBV. Toussi et al. [21] in New York, USA, also found that children who are HIV-HBV-coinfected had a higher median age of 17 years compared to HIV-monoinfected children with a median age of 11.4 years. Also in Tanzania [20], the only 2 children that were seropositive for HBsAg was in the age group of 6–10 years, although this finding was not statistically significant. In contrast, there was no age group risk of sero-positivity for HBsAg in the study by Sadof et al. [6]. In Nigeria, Hepatitis B vaccine was first introduced as part of the National Program on Immunization in 2004, and this may partly explain the reason for a higher HBs Ag sero-positivity among subjects within 11–15 years group. This assumption could have been buttressed by the fact that HBV infection was also found to be significantly more among our subjects who had none or did not complete HBV immunization. However, since the introduction of Hepatitis B vaccine in 2004, its coverage has increased steadily from 18% in 2005 to 66% in 2010 with an unfortunate decline to 50% in 2011 [29]. Another potential route of transmission, especially through sexual exposure, may be difficult to ascertain among adolescents. Although the majority of our subjects (27, 79.9%) also appears to have acquired HIV via MTCT, this finding was not significant, and only 6 subjects (3.8%), co-infected with HBV, were 5 years and below. Mindful of the shared mode of transmission of HIV and HBV, vertical transmission of HBV cannot be substantiated in our study as more subjects less than 5 years of age would have been expected to be HIV-HBV co-infected. Although Mbaawuaga et al. [10] had demonstrated a high sero-prevalence of 11% of HBV infection among pregnant women in Makurdi, the low infectivity rate of 3.3%, a major determinant of perinatal transmission found in their study, may also have explained this low prevalence of HBV among the underfives in our study.

More female subjects (19, 10%) were dually infected with HIV and HBV than male subjects (12, 5.9%), but this was not statistically significant. The import of this finding may not be readily discernible.

Our data indicated that the majority of, albeit insignificant, HIV-HBV-coinfected subjects were recruited early in WHO Clinical stages 1 and 2 disease but presented with a lower median CD4 count. A significant majority of the HIV-HBV co-infected children in the present study, also presented at a much reduced CD4 of ≤ 15%. Although, individuals with WHO clinical stages 1 and 2 have been well known to have substantially reduced CD4% and thus may explain the discordance between the CD4% and the WHO clinical stages as also found in the present study. In Rawizza et al. [7] study, CD4 cell count and WHO clinical stage were not significantly different between HIV-HBV-coinfected and HIV-monoinfected children.

The effect of HIV-HBV co-infections on HIV replication in our study is not clearly defined as the mean viral load among the HIV-HBV-coinfected subjects was insignificantly lower than that among the HIV-monoinfected subjects. Toussi et al. [21] in New York, however, showed undeniably that HIV-HBV-coinfected children tended to be more symptomatic (CDC category C) and had a lower CD4% and a higher HIV RNA levels than their monoinfected counterparts.

Although other accompanying opportunistic infections may also have explained the reduced CD4 count among our HIV-HBV-coinfected patients, this confounding factor was outside the scope of present study.

In this study, a higher median and hepatotoxic ALT values among the HIV-HBV-coinfected subjects compared to the HIV-monoinfected group were not statistically significant. Similar data were obtained by Rawizza et al. [7] who also did not find significant differences in elevated ALT between the two HBV status groups. In China, Zhou et al. [23] also reported that although mildly elevated ALT was higher in HIV-HBV-coinfected group compared to HIV-monoinfected counterpart, the difference was not significant. In Tanzania [20] study, elevated ALT value was associated with HIV-HBV co-infections in the univariate analysis but not in multivariate analysis. Although longitudinal study of the impact of HBV on ALT activities among our HIV-infected children in the long term is desirable, HBV has been reported earlier [30] to be a cause of elevated liver enzymes as also found in this study. Liver biopsy, the gold standard for assessing disease severity in HIV-HBV coinfection, is however outside the scope of this study.

In most developing countries including Nigeria and in our center, the first line HAART for our patients included a regimen containing 3TC/AZT backbone. Although, the efficacy of 3TC against HBV has been proven by Dore et al. [31] with the CAESAR study, 3TC based regimen had also been associated with a rapid development of resistance to HBV [32]. These findings have influenced the evolution of new treatment algorithms, wherein TDF and 3TC/FTC are included as the nucleoside backbone, irrespective of prior exposure to lamivudine [33]. This new nucleoside backbone itself is associated with a good HBV DNA suppression and normalization of the alanine transaminase level [33]. Fortunately, TNF is now approved for use in special circumstances (possibly HIV-HBV coinfection) among children from the age of 2 years [34].

A paradigm shift to include this new nucleoside backbone as part of first line HAART may become inevitable as this study and those of others [6–8] had shown consistently a high prevalence of HIV-HBV co-infection among Nigerian children.
5. Conclusion

The present study had revealed a high prevalence of 7.8% of HBsAg among our HIV-infected children and underscored the predominance of HBV infection among young adolescent subjects aged 11–15 years and the import of HBV immunization as significantly more subjects with none or incomplete HBV vaccination were infected. It also revealed that HBs antigenemia occurred significantly more among subjects with severe immunosuppression.

It is therefore recommended that all pediatric HIV-infected patients should be screened for HBV on recruitment into care and treatment. Also, efforts aimed at increasing the coverage and completeness of HB vaccination via the strengthening of the Nigerian Expanded Program on Immunization can also not be overemphasized. Moreover, antenatal screening of HBV among pregnant women should be intensified, and the neonate of those found positive should be offered both passive and active immunization. Furthermore, longitudinal study on the impact of HIV-HBV co-infection on immune recovery, HIV and HBV viral replication, and hepatotoxicity over time is desirable and also recommended.

Conflict of Interests

The authors declare that they have no conflict of interests.

Authors’ Contributions

Emmanuel Ademola Anigilaje and Ayodotun Olutola both contributed to the conception, the design, acquisition, analysis, and interpretation of data. Both authors were involved in drafting the paper and revising it critically for important intellectual content, and the two authors also gave final approval of the version to be published.

Acknowledgments

The authors would like to acknowledge and thank all patients and staff, especially Dr. J. Abah, the Principal Coordinator of the APIN/Harvard PEPFAR program at Federal Medical Centre, Makurdi, Benue State, Nigeria.

References

[1] Global HIV/AIDS Response, “Epidemic update and health sector progress towards Universal Access,” Progress Report, 2011.
[2] Federal Ministry of Health, ANC HIV Sentinel Survey, Federal Ministry of Health, Abuja, Nigeria, 2010.
[3] Federal Ministry of Health, National Guidelines for Paediatric HIV and AIDS Treatment and Care, Federal Ministry of Health, Abuja, Nigeria, 2007.
[4] A. Ojoawo, O. Dairo, and A. Ojetunde, Eds., City Profile of HIV/AIDS in the City of Makurdi, Nigeria, The Development Policy Centre, Ibadan, Nigeria, 2005.
[5] World Health Organization, Introduction of Hepatitis B into Childhood Immunization Services: Management Guidelines, Including Information for Health Workers and Parents, World Health Organization, Geneva, Switzerland, 2001.
[6] A. E. Sadoh, W. E. Sadoh, and N. J. Idioryikeyemwen, “HIV co-infection with hepatitis B and C viruses among Nigerian children in an antiretroviral treatment programme,” SAJCH South African Journal of Child Health, vol. 5, supplement 1, pp. 7–10, 2011.
[7] H. Rawizza, S. Ochigbo, C. Chang et al., “Prevalence of hepatitis co-infection among HIV infected Nigerian children in the Harvard PEPFAR ART program,” in Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, NC, USA, February 2010, Poster abstract S-181, http://retroconfconference.org/2010/Abstracts/39148.htm.
[8] G. M. Ashir, A. I. Rabasa, M. M. Gofama, D. Bubuk, H. Abubakar, and G. A. Farouk, “Study of hepatic functions and prevalence of hepatitis B surface antigenemia in Nigerian children with human immunodeficiency virus infection,” Nigerian Journal of Medicine, vol. 18, supplement 30, pp. 260–262, 2009.
[9] F. Rouet, M. L. Chaix, A. Inwoley et al., “Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1 infected children,” Clinical Infectious Diseases, vol. 46, no. 3, pp. 361–366, 2008.
[10] E. M. Mbaawuaga, M. N. O. Enenebeaku, J. A. Okopi, and J. G. Damen, “Hepatitis B Virus (HBV) infection among pregnant women in Makurdi, Nigeria,” African Journal Biomedical Research, vol. 11, no. 2, pp. 155–159, 2008.
[11] J. F. Colin, D. Cazals-Hatem, M. A. Loriot et al., “Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men,” Hepatology, vol. 29, no. 4, pp. 1306–1310, 1999.
[12] H. Oshitani, F. C. Kasolo, M. Mpabalwani et al., “Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 90, no. 3, pp. 235–236, 1996.
[13] M. E. Mendy, T. Welzel, O. A. Lesi et al., “Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in the Gambia, West Africa,” Journal of Viral Hepatitis, vol. 17, supplement 2, pp. 115–122, 2010.
[14] M. F. Yuen, Y. Tanaka, D. Y. T. Fong et al., “Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B,” Journal of Hepatology, vol. 50, no. 1, pp. 80–88, 2009.
[15] A. Eskild, P. Magnus, G. Petersen et al., “Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS,” AIDS, vol. 6, no. 6, pp. 571–574, 1992.
[16] R. J. C. Gilson, A. E. Hawkins, M. R. Beecham et al., “Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection,” AIDS, vol. 11, no. 5, pp. 597–606, 1997.
[17] C. Livry, C. Binquet, C. Sgro et al., “Acute liver enzyme elevations in HIV-1-infected patients,” HIV Clinical Trials, vol. 4, no. 6, pp. 400–410, 2003.
[18] M. Puoti, C. Torti, D. Ripamonti et al., “Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome,” Journal of Acquired Immune Deficiency Syndromes, vol. 32, no. 3, pp. 259–267, 2003.
[19] HIV/AIDS, Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach: 2010 Revision, 2010.
[20] S. P. Telatela, M. I. Matee, and E. K. Munubhi, “Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania,” *BMC Public Health*, vol. 7, p. 338, 2007.

[21] S. S. Toussi, J. Abadi, M. Rosenberg, and D. Levanon, “Prevalence of hepatitis B and C virus infections in children infected with HIV,” *Clinical Infectious Diseases*, vol. 45, no. 6, pp. 795–798, 2007.

[22] R. Chakraborty, G. Rees, D. Bourboulia et al., “Viral coinfections among African children infected with human immunodeficiency virus type 1,” *Clinical Infectious Diseases*, vol. 36, no. 7, pp. 922–924, 2003.

[23] S. Zhou, Y. Zhao, Y. He et al., “Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 54, supplement 2, pp. 191–196, 2010.

[24] W. Jafri, N. Jafri, J. Yakoo et al., “Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan,” *BMC Infectious Diseases*, vol. 6, p. 101, 2006.

[25] E. I. Ugwuja and N. C. Ugwu, “Seroprevalence of hepatitis B surface antigen and liver function tests among adolescents in Abakaliki, South Eastern Nigeria,” *Internet Journal of Tropical Medicine*, vol. 6, no. 1, p. 7, 2009.

[26] J. A. Ndako, G. O. N. Echeonwu, A. O. Olabode et al., “Seroprevalence of hepatitis B surface antigen (HBsAg) among children of primary school age in a community, North-Central, Nigeria,” *Sierra Leone Journal of Biomedical Research*, vol. 2, supplement 1, pp. 32–37, 2010.

[27] I. A. Angyo and A. M. Yakubu, “Lack of association between some risk factors and hepatitis B surface antigenaemia in children with sickle cell anaemia,” *West African Journal of Medicine*, vol. 20, supplement 3, pp. 214–218, 2001.

[28] D. N. Bukbuk, A. P. Bassi, and Z. M. Mangoro, “Sero-prevalence of hepatitis B surface antigen among primary school pupils in rural Hawal valley, Bornu State, Nigeria,” *J Comm Med PHC*, vol. 17, supplement 1, pp. 20–23, 2005.

[29] WHO/UNICEF, “Estimatesofhepb3. coverage,” 2012, http://apps.who.int/immunization_monitoring/en/globalsummary/time-series/tswucovagehepb3.htm.

[30] M. S. Sulkowski, D. L. Thomas, R. E. Chaisson, and R. D. Moore, “Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection,” *Journal of the American Medical Association*, vol. 283, no. 1, pp. 74–80, 2000.

[31] G. J. Dore, D. A. Cooper, C. Barrett, L. E. Goh, B. Thakrar, and M. Atkins, “Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR),” *Journal of Infectious Diseases*, vol. 180, no. 3, pp. 607–613, 1999.

[32] G. V. Matthews, A. Bartholomeusz, S. Locarnini et al., “Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy,” *AIDS*, vol. 20, no. 6, pp. 863–870, 2006.

[33] “HIV and hepatitis B co-infection,” in *Background Document*, A. E. Singh and T. Wong, Eds., pp. 1–43, 2009.

[34] “Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection,” 2012, http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf.